Mar. 3 at 3:09 PM
$QUCY
An
$8.28M market cap targeting a projected
$6.38B PDAC diagnostics market by 2029 is the definition of asymmetry. Early-stage biotech attracts attention when valuation and addressable market sit on different planets. Mainz Biomed trades at microcap levels while operating in cancer early detection - a segment where validated products can scale rapidly if clinically proven and reimbursed
For context,
$EXAS reached roughly
$400 -500M market cap pre-FDA in 2014 and later exceeded
$15B at peak after Cologuard commercialization.
$GH IPO’d around
$1.6B and later traded above
$7B. These are not comparisons of quality or probability - they illustrate how large oncology diagnostics can become once regulatory and commercial hurdles are cleared
If MYNZ captured just 0.1% of a
$6.38B market, that implies ~
$6.38M annual revenue. At a hypothetical 5x P/S multiple, valuation would approximate ~
$32M - nearly 4x current levels. This is not a forecast, only a mathematical illustration of optionality
